ライフサイエンスコーパス: abscessus

1 erm(41) genotype is a useful adjunct for M. abscessus.

2 table to test antibiotic activity against M. abscessus.

3 of inhibitors against TrmD in Mycobacterium abscessus.

4 showed promising in vivo activity against M. abscessus.

5 rium avium complex (MAC) and 69 (36%) for M. abscessus.

6 bserved in M. marinum and the smallest in M. abscessus.

7 ycobacteria including M. tuberculosis and M. abscessus.

8 topic shifts from incorporation of 15N in M. abscessus.

9 enum varied from those of M. chelonae and M. abscessus.

10 solates of M. chelonae and 25 isolates of M. abscessus.

11 t distinguish Mycobacterium chelonae from M. abscessus.

12 ne sequencing to identify M. chelonae and M. abscessus.

13 tiate M. immunogenum from M. chelonae and M. abscessus.

14 ting that this clone is a subgroup within M. abscessus.

15 erial species Mycobacterium fortuitum and M. abscessus.

16 The isolates were later identified as M. abscessus.

17 ers Mycobacterium smegmatis or Mycobacterium abscessus.

18 esence of global transmission networks of M. abscessus.

19 n reliably identify cross-transmission in M. abscessus.

20 and phylogenetically close to Mycobacterium abscessus.

21 life-threatening infections of Mycobacterium abscessus.

22 of a series of indolecarboxamides against M. abscessus.

23 bination works synergistically to inhibit M. abscessus.

24 occur during chronic lung infection with M. abscessus.

25 20% of U.S. isolates of M. abscessus subsp. abscessus.

26 which we propose the name "Para-streptomyces abscessus."

27 l isolates identified 2 clonal strains of M. abscessus; 1 clone was isolated from water sources at a

28 acterized clinical isolates comprising 29 M. abscessus, 15 M. massiliense, and 2 M. bolletii isolates

29 terium avium complex (72%) and Mycobacterium abscessus (16%) were the most common species.

30 M. abscessus (34%) and M. avium complex (83%) were the most

31 Mycobacterium abscessus (34%) and Mycobacterium avium complex (83%) we

32 or rapidly growing mycobacteria (98% were M. abscessus), 78% (29 of 37) for M. kansasii, and 26% (9 o

33 Mycobacterium abscessus, a rapidly growing nontuberculous mycobacteriu

34 Lung infections with Mycobacterium abscessus, a species of multidrug-resistant nontuberculo

35 iduals with cystic fibrosis (CF), in whom M. abscessus accelerates inflammatory lung damage, leading

36 the 2.9- angstrom resolution structure of M. abscessus AftD, determined by single-particle cryo-elect

37 strain, independent clinical isolates of M. abscessus also readily establish infection and prolifera

38 ong the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM.

39 alues for 81 isolates of M. abscessus subsp. abscessus and 12 isolates of M. abscessus subsp. massili

40 identified 41 Mycobacterium abscessus subsp. abscessus and 13 M. abscessus subsp. massiliense isolate

41 A total of 82 isolates (58 M. abscessus and 24 M. chelonae isolates) were tested blind

42 hods, 46 of the isolates were found to be M. abscessus and 29 were identified as M. chelonae.

43 erm(41) sequencing of 285 M. abscessus and 45 M. chelonae isolates was compared to 14

44 l sequencing) is required for division of M. abscessus and closely related species.

45 of two clonal groups for M. abscessus subsp. abscessus and five clonal groups for M. abscesssus subsp

46 reviously identified as being M. chelonae/M. abscessus and identified M. massiliense from isolates fr

47 g of M. fortuitum against clarithromycin; M. abscessus and M. chelonae against the aminoglycosides; a

48 ld be able to easily identify isolates of M. abscessus and M. chelonae.

49 may be helpful for distinguishing between M. abscessus and M. chelonae.

50 rculosis as well as against intracellular M. abscessus and M. leprae, indicating their potential as t

51 enome, regions that discriminated between M. abscessus and M. massiliense were identified through arr

52 d three pairs of closely related strains: M. abscessus and M. massiliense, M. mucogenicum and M. phoc

53 ounds exhibit activity against planktonic M. abscessus and M. tuberculosis as well as against intrace

54 Mycobacterium abscessus and Mycobacterium chelonae are two closely rel

55 rly for distinguishing between Mycobacterium abscessus and Mycobacterium chelonae.

56 healthcare-associated transmission in two M. abscessus and two M. avium clusters.

57 olates were typed as M. abscessus subspecies abscessus and were clonally related within each patient.

58 oscopes and endoscopic cleaning machines (M. abscessus) and contaminated hospital water supplies (M.

59 cterial infections against M tuberculosis, M abscessus, and M chimaera.

60 tes of N. cyriacigeorgica, N. asteroides, N. abscessus, and N. otitidiscaviarum were susceptible to t

61 bmitted as M. chelonae were identified as M. abscessus, and one isolate submitted as M. abscessus was

62 cterium fortuitum group, three Mycobacterium abscessus, and three Mycobacterium chelonae isolates) we

63 rium fortuitum group, three of Mycobacterium abscessus, and three of Mycobacterium chelonae) were tes

64 Infections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosi

65 bacterial infections caused by Mycobacterium abscessus are responsible for a range of disease manifes

66 metic mean = 1.5% of hsp65 sequences) and M. abscessus (arithmetic mean = 0.006% of hsp65 sequences).

67 he hflX gene in the pathogenic Mycobacterium abscessus, as well as the nonpathogenic Mycobacterium sm

68 tigated a biphasic outbreak of Mycobacterium abscessus at a tertiary care hospital.

69 Based on the M. abscessus ATCC 19977(T) genome, regions that discriminat

70 We report the first series of Mycobacterium abscessus bacteremia after cytokine-induced killer cell

71 tibility breakpoints for M. abscessus subsp. abscessus be changed from </=2 to </=4 mug/ml and that i

72 ly effective at preventing infection with M. abscessus because it is a ubiquitous environmental sapro

73 the direct competitive inhibition of the M. abscessus beta-lactamase, Bla(Mab), using a novel assay,

74 subcutaneously significantly reduced lung M. abscessus burden.

75 ot be used to infer cross-transmission in M. abscessus but does provide enough information to replace

76 ucible macrolide resistance in Mycobacterium abscessus but not Mycobacterium chelonae.

77 stinguishable from Mycobacterium chelonae/M. abscessus by partial 16S rRNA gene sequencing.

78 s demonstrates that the inability to type M. abscessus by PFGE is associated with a single clone of o

79 of using thiourea-containing buffer with M. abscessus by studying 69 isolates not previously typeabl

80 resistance in Mycobacterium abscessus subsp. abscessus, calling into question the usefulness of macro

81 M. abscessus can transition between a noninvasive, biofilm-

82 ses (57%; odds ratio = 0.7, P < 0.05) and M. abscessus cases (51%; odds ratio = 0.5, P < 0.01) than i

83 Mycobacterium abscessus causes disease in patients with structural abn

84 tidolipid in the outermost portion of the M. abscessus cell wall masks underlying cell wall lipids in

85 microparticles generated from Mycobacterium abscessus cell walls.

86 cy of this combination against a panel of M. abscessus clinical isolates, revealing the therapeutic p

87 ion profiles, especially among Mycobacterium abscessus clinical isolates.

88 iability and showed enhanced effects on a M. abscessus clinical strain when combined with amikacin.

89 s provides an explanation whereby initial M. abscessus colonization of abnormal lung airways escapes

90 hromogenicum (11 of 11), and the M. chelonae-abscessus complex (21 of 21).

91 Multi-drug resistant Mycobacterium abscessus complex (MABSC) is a form of Nontuberculous my

92 Members of the Mycobacterium chelonae-abscessus complex (MCAC) are close to the mycobacterial

93 equencing (26 isolates of the M. chelonae-M. abscessus complex and 64 remaining isolates, including M

94 Forty-one Mycobacterium abscessus complex isolates from 17 pediatric cystic fibr

95 hods differentiate between members of the M. abscessus complex.

96 farcinica, 12 N. otitidiscaviarum, and 10 N. abscessus cultures were studied.

97 ceptibility by overexpressing Bla(Mab) in M. abscessus, demonstrating relebactam-Bla(Mab) target enga

98 cterium avium complex [MAC] or Mycobacterium abscessus) disease.

99 t support this being a major mechanism for M abscessus dissemination at a national level in England.

100 actam, in combination with the front line M. abscessus drug imipenem.

101 ium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Rese

102 trophils treated with azithromycin killed M. abscessus equally as well as untreated neutrophils from

103 g susceptibility testing, all isolates of M. abscessus exhibited resistance to tobramycin (MIC of 8 t

104 M. abscessus exists as either a glycopeptidolipid (GPL) exp

105 Conversely, M. abscessus expressing GPL does not stimulate expression o

106 s thought to be colonized with Mycobacterium abscessus for 13 yr prior to developing clinically appar

107 Blood cultures grew M. abscessus for all patients, and admission peripheral blo

108 del to investigate pulmonary Mycobacteroides abscessus (formerly Mycobacterium abscessus) infection i

109 g were done on 168 consecutive isolates of M abscessus from 31 patients attending an adult cystic fib

110 The release of M. abscessus from apoptotic macrophages initiated the forma

111 -confirmed colonization or infection with M. abscessus from January 2013 through December 2015.

112 Isolates of M. abscessus from sputum do not always reflect the entire d

113 cobacteria (RGM), particularly Mycobacterium abscessus, from individuals with cystic fibrosis (CF) is

114 is facilitated by biofilm formation, with M. abscessus glycopeptidolipids playing an important role.

115 Consistent with this prediction, M. abscessus grew on both steroids.

116 es efficiently, and a DeltahsaD mutant of M. abscessus grew on neither steroid.

117 Members of the Mycobacterium abscessus group (MAG) cause lung, soft tissue, and disse

118 e M. avium complex (MAC), the M. chelonae-M. abscessus group (MCAG), the M. fortuitum group (MFG), an

119 bscessus (M. abscessus sensu lato, or the M. abscessus group) comprises three closely related taxa wh

120 Mycobacterium massiliense (Mycobacterium abscessus group) is an emerging pathogen causing pulmona

121 e erm(41) and rrl genes in the Mycobacterium abscessus group, a multiplex real-time PCR assay for cla

122 cation within 24 h after isolation of the M. abscessus group.

123 iotin cofactor synthesis was required for M. abscessus growth due to increased intracellular biotin d

124 ugh colony morphology shift in Mycobacterium abscessus has been implicated in loss of glycopeptidolip

125 Mycobacterium abscessus has emerged as a major pathogen in cystic fibr

126 Mycobacterium abscessus has emerged as an important cause of lung infe

127 ncluding M. immunogenum, M. chelonae, and M. abscessus, have been associated with nosocomial infectio

128 ch is a major virulence factor that makes M. abscessus highly cytotoxic to mouse macrophages, and tha

129 tween the smooth and rough morphotypes of M. abscessus However, in cystic fibrosis neutrophils, wortm

130 t evidence of within-patient subclones of M. abscessus in adults with CF suggests the possibility tha

131 to define the mechanisms of acquisition of M abscessus in individuals with cystic fibrosis.

132 As the pathogenic mechanisms of M. abscessus in the context of the lung are not well-unders

133 The incidence rate of M. abscessus increased from 0.7 cases per 10000 patient-day

134 Azithromycin did not affect M. abscessus-induced neutrophil reactive oxygen species for

135 sphate (ABL/PI5P) were tested in vitro in M. abscessus-infected macrophages from PWCF as potential tr

136 cording in the in vivo physiopathology of M. abscessus infection and emphasizes cording as a mechanis

137 We developed a mouse model of pulmonary M. abscessus infection using the aerosolized route of infec

138 c fibrosis with a disseminated Mycobacterium abscessus infection was treated with a three-phage cockt

139 from nine non-CF patients with persistent M. abscessus infection were characterized by colony morphol

140 3 drugs usually combined for treatment of M. abscessus infection, cefoxitin was the most active becau

141 Alternative routes of acquisition of M. abscessus infection, in particular the environment, requ

142 a prospective advance in the treatment of M. abscessus infection; increasing the susceptibility of th

143 acteroides abscessus (formerly Mycobacterium abscessus) infection in an immunocompetent mouse strain,

144 ty, but the transplants did not clear the M. abscessus infections and both patients died as a result

145 al isolates, we show that the majority of M. abscessus infections are acquired through transmission,

146 eria-specific diagnostic to differentiate M. abscessus infections from underlying pulmonary disease i

147 Conventional imaging cannot distinguish M. abscessus infections from underlying pulmonary disease o

148 The prognosis of Mycobacterium abscessus infections is poor due to the lack of effectiv

149 d chemical structure class active against M. abscessus infections with promising translational develo

150 The same has been observed for M. abscessus infections, which are very difficult to treat;

151 macrolides for treating M. abscessus subsp. abscessus infections.

152 mmunomodulatory effects, is used to treat M. abscessus infections.

153 Mycobacterium abscessus is a fast-growing, multidrug-resistant organis

154 Mycobacterium abscessus is a rapidly growing environmental mycobacteri

155 Mycobacterium abscessus is a rapidly growing mycobacterial species whi

156 Mycobacterium abscessus is a rapidly growing Mycobacterium causing a w

157 e is still conflicting evidence as to how M. abscessus is acquired and whether cross-transmission occ

158 Mycobacterium abscessus is an extensively drug-resistant pathogen that

159 Mycobacterium abscessus is an important cause of water-related nosocom

160 direct patient-to-patient transmission of M. abscessus is critically important in directing an infect

161 differentiation of these two species from M. abscessus is difficult and relies on the sequencing of o

162 Among these, Mycobacterium abscessus is particularly refractory owing to its extens

163 sts healthcare-associated transmission of M. abscessus is rare and includes a report of potential hea

164 Mycobacterium abscessus is resistant to multiple antibiotics, creating

165 Mycobacterium abscessus is the most common cause of rapidly growing my

166 It appears that M. abscessus is transported to the CNS within macrophages.

167 ink and a skin biopsy) and 11 Mycobacterium abscessus isolates (5 from the implicated bottle of gray

168 activity in vitro against a wide panel of M. abscessus isolates and in infected macrophages.

169 ed whole-genome sequencing of 11 clinical M. abscessus isolates derived from eight U.S. patients with

170 -genome sequencing data demonstrated that M. abscessus isolates from 16 patients were unrelated, diff

171 tively sequenced the whole genomes of 145 M. abscessus isolates from 62 patients, seen at 4 hospitals

172 The M. abscessus isolates from case patients and the supplement

173 Whole-genome sequencing was applied to 27 M. abscessus isolates from the 20 patients in this cohort t

174 liense and 15% to 20% of M. abscessus subsp. abscessus isolates renders these species intrinsically m

175 .S. and Western European M. abscessus subsp. abscessus isolates that are genetically distinct from ot

176 Previous population studies of clinical M. abscessus isolates utilized multilocus sequence typing o

177 and 145 clinical isolates (58 MAC and 87 M. abscessus isolates), including 54 clarithromycin- and/or

178 d to the unambiguous identification of 26 M. abscessus isolates, 7 M. massiliense isolates, and 2 M.

179 testing by Etest of four carbapenems for M. abscessus isolates.

180 mited by a lack of WGS from environmental M. abscessus isolates.

181 urate erm(41) genotype results for all 87 M. abscessus isolates.

182 coside resistance levels of 50 Mycobacterium abscessus isolates.

183 rdonae, and 5 M. chelonae group (all were M. abscessus) isolates.

184 nd mitigated a 2-phase clonal outbreak of M. abscessus linked to hospital tap water.

185 cal to the CLSI guidelines for Mycobacterium abscessus: </=16 mug/ml for susceptible, 32 mug/ml for i

186 bronchiectasis and refractory Mycobacterium abscessus lung disease was treated for 6 months with a t

187 our-drug combination in a murine model of M. abscessus lung infection.

188 Mycobacterium abscessus (M. abscessus sensu lato, or the M. abscessus

189 Mycobacterium abscessus (M. abscessus) was the species most likely to

190 ough, wild-type human clinical isolate of M. abscessus (M. abscessus-R) and a smooth, attenuated muta

191 PCR for straightforward identification of M. abscessus, M. massiliense, and M. bolletii and the asses

192 ion and typing of 42 clinical isolates of M. abscessus, M. massiliense, and M. bolletii from patients

193 PCR-based method for distinguishing among M. abscessus, M. massiliense, and M. bolletii.

194 ates with ambiguous species identities as M. abscessus-M. massiliense by rpoB, hsp65, and secA sequen

195 verscores resistance and that isolates of M. abscessus/M. chelonae from CF patients are more likely t

196 Mycobacterium abscessus (Mab) is a rapidly growing species of multidru

197 Mycobacterium abscessus (Mabs) is a rapidly growing Mycobacterium and

198 denylyltransferase (PPAT) from Mycobacterium abscessus (Mabs).

199 M. tuberculosis (MtMetX), Mycolicibacterium abscessus (MaMetX), and Mycolicibacterium hassiacum (MhM

200 Insight into the immune control of M. abscessus may provide novel targets of therapy.

201 tutions in their tail spike proteins, and M. abscessus mutants resistant to TPP-independent phages re

202 were characterized in a MIC assay against M. abscessus, Mycobacterium intracellulare, Mycobacterium s

203 also in few samples containing Mycobacterium abscessus,Mycobacterium gordonae, o rMycobacterium therm

204 acteria (41%), fungi (10%) and Mycobacterium abscessus, Mycoplasma hominis and Lactobacillus sp. (one

205 ubsp. bolletii (n = 24), M. abscessus subsp. abscessus (n = 6), Mycobacterium fortuitum (n = 3), Myco

206 re used to identify 75 isolates as either M. abscessus or M. chelonae that were originally submitted

207 antimicrobial activity against Mycobacterium abscessus or Pseudomonas aeruginosa could be detected.

208 o Mycobacterium avium, M. intracellulare, M. abscessus, or M. massiliense and three healthy controls

209 who presented with multifocal Mycobacterium abscessus osteomyelitis (patient 1) and disseminated CMV

210 derable time on the same wards with other M. abscessus-positive patients.

211 ulous mycobacteria, especially Mycobacterium abscessus, post-transplantation survival has not been de

212 We studied 118 strains of M. abscessus previously studied by PFGE by randomly amplifi

213 y (PET) was performed in a mouse model of M. abscessus pulmonary infection and in a patient with micr

214 s for initial proliferation and sustained M. abscessus pulmonary infection and permits evaluation of

215 ynamic (11)C-PABA PET in a mouse model of M. abscessus pulmonary infection rapidly distinguished infe

216 fibrosis and microbiologically confirmed M. abscessus pulmonary infection was safe and demonstrated

217 patient with microbiologically confirmed M. abscessus pulmonary infection.

218 erved that the increased virulence of the M. abscessus R variant compared with the S variant correlat

219 ast-mycobacterium microcolony assay, with M. abscessus-R exhibiting growth characteristics similar to

220 phagocyte aggregates develop at sites of M. abscessus-R infection, but are absent with M. abscessus-

221 We have found that M. abscessus-R is able to persist and multiply in a murine

222 M. abscessus-R is able to persist and multiply in human mon

223 M. abscessus-R resides in a phagosome typical for pathogeni

224 e human clinical isolate of M. abscessus (M. abscessus-R) and a smooth, attenuated mutant (M. abscess

225 Recently, two new M. abscessus-related species, M. massiliense and M. bolleti

226 FF-NH(2) leverages intrinsic M. abscessus resistance conferred by the transcription fact

227 The M. abscessus rough (R) variant, devoid of cell-surface glyc

228 reported for virulent M. tuberculosis and M. abscessus-S exhibiting growth characteristics similar to

229 bscessus-R infection, but are absent with M. abscessus-S infection.

230 st and multiply in human monocytes, while M. abscessus-S is deficient in this ability.

231 In contrast, M. abscessus-S resides in a "loose" phagosome with the phag

232 clude that a mutation has occurred in the M. abscessus-S variant which has altered the ability of thi

233 essus-R) and a smooth, attenuated mutant (M. abscessus-S) which spontaneously dissociated from the cl

234 pulmonary infection model in contrast to M. abscessus-S, which is rapidly cleared.

235 Mycobacterium abscessus (M. abscessus sensu lato, or the M. abscessus group) compris

236 onomic statuses are under revision, i.e., M. abscessus sensu stricto, Mycobacterium bolletii, and Myc

237 cobacterium immunogenum, M. chelonae, and M. abscessus, showed various susceptibilities to the glutar

238 udy we demonstrate that rough variants of M. abscessus stimulate the human macrophage innate immune r

239 eport herein the draft genome sequence of M. abscessus strain 47J26.

240 ives that efficiently kill the infectious M. abscessus strain were developed by genome engineering an

241 ern) occurs with almost 50% of Mycobacterium abscessus strains during pulsed-field gel electrophoresi

242 We found that patients acquired unique M. abscessus strains even after spending considerable time

243 xplores the genomic diversity of clinical M. abscessus strains from multiple continents and provides

244 om 3 confirmed infections grew Mycobacterium abscessus strains that were indistinguishable by pulsed-

245 PCR can be used for genetic comparison of M. abscessus strains, including strains which cannot be com

246 of a patient with disseminated Mycobacterium abscessus, Streptococcus viridians bacteremia, and cytom

247 meric models for the Mabellini Mycobacterium abscessus structural proteome database.

248 urate approach for discriminating MAC and M. abscessus (sub)species and for detecting clarithromycin

249 The accuracies of MAC and M. abscessus (sub)species identification were 92.1% (35/38)

250 Clarithromycin resistance in Mycobacterium abscessus subsp.

251 m a large hospital-associated outbreak of M. abscessus subsp.

252 ental acquisition of outbreak isolates of M. abscessus subsp.

253 Environmental M. abscessus subsp.

254 erium abscessus subsp. bolletii (n = 24), M. abscessus subsp. abscessus (n = 6), Mycobacterium fortui

255 tedizolid MIC90 values for 81 isolates of M. abscessus subsp. abscessus and 12 isolates of M. abscess

256 bases accurately identified 41 Mycobacterium abscessus subsp. abscessus and 13 M. abscessus subsp. ma

257 ted the presence of two clonal groups for M. abscessus subsp. abscessus and five clonal groups for M.

258 ithromycin susceptibility breakpoints for M. abscessus subsp. abscessus be changed from </=2 to </=4

259 the usefulness of macrolides for treating M. abscessus subsp. abscessus infections.

260 ssus subsp. massiliense and 15% to 20% of M. abscessus subsp. abscessus isolates renders these specie

261 closely related U.S. and Western European M. abscessus subsp. abscessus isolates that are genetically

262 Sequencing of the erm gene of M. abscessus subsp. abscessus will predict inducible macrol

263 ucible macrolide resistance in Mycobacterium abscessus subsp. abscessus, calling into question the us

264 ing approximately 20% of U.S. isolates of M. abscessus subsp. abscessus.

265 The species identified were Mycobacterium abscessus subsp. bolletii (n = 24), M. abscessus subsp.

266 eregrinum and a nonfunctional erm gene in M. abscessus subsp. massiliense and 15% to 20% of M. absces

267 cterium abscessus subsp. abscessus and 13 M. abscessus subsp. massiliense isolates identified by whol

268 essus subsp. abscessus and 12 isolates of M. abscessus subsp. massiliense were 8 mug/ml and 4 mug/ml,

269 All 50 isolates were typed as M. abscessus subspecies abscessus and were clonally related

270 vium complex (MAC) species and Mycobacterium abscessus subspecies and for determining clarithromycin

271 utbreaks of near-identical isolates of the M abscessus subspecies massiliense (from 11 patients), dif

272 The clusters of M abscessus subspecies massiliense showed evidence of tran

273 patient with a drug-resistant Mycobacterium abscessus suggests that phages may have considerable pot

274 eased cell envelope fluidity and promoted M. abscessus survival in the alkaline lung environment.

275 ients with genetically related strains of M. abscessus that had been previously typed by variable-num

276 genome sequencing (WGS) on 32 isolates of M. abscessus that were taken from multiple body sites of 2

277 monstrated for the fast grower Mycobacterium abscessus, the compound is potent in vitro and in vivo,

278 patients in this study have not acquired M. abscessus through direct patient-to-patient transmission

279 and spread of the environmental organism M. abscessus through the global cystic fibrosis population,

280 The intrinsic resistance of M. abscessus to most commonly available antibiotics serious

281 A search for alternative Mycobacterium abscessus treatments led to our interest in the two-comp

282 smear patterns were identical to those of M. abscessus type strain ATCC 19977, which had a nonsmear p

283 Both M. abscessus variants also have distinctive growth patterns

284 t respiratory epithelial cells respond to M. abscessus variants lacking GPL with expression of IL-8 a

285 ese studies increase our understanding of M. abscessus virulence and of neutrophil mycobactericidal m

286 Mycobacterium abscessus was also isolated from respiratory specimens (

287 . abscessus, and one isolate submitted as M. abscessus was found to be M. chelonae.

288 Previously, M. abscessus was thought to be independently acquired by su

289 y in M. chelonae), and cefoxitin (only in M. abscessus) was shown.

290 Mycobacterium abscessus (M. abscessus) was the species most likely to cause clinical

291 s a significant resistance determinant in M. abscessus We demonstrate that mycobacterial HflX associa

292 Mycobacterium species -- M. smegmatis and M. abscessus -- we demonstrate a striking conservation of t

293 M. avium, M. mucogenicum, and Mycobacterium abscessus were found to persist most frequently.

294 ncident NTM infections from either MAC or M. abscessus were less likely to have had chronic azithromy

295 eorgica, N. asteroides, N. farcinica, and N. abscessus were only moderate resistant.

296 Several bacterial species, including M. abscessus, were cultured from an opened multidose supple

297 Five outbreaks due to M. abscessus which gave broken DNA by PFGE gave evaluable p

298 uberculous mycobacterium (NTM) Mycobacterium abscessus, which causes progressive lung damage and is e

299 ncing of the erm gene of M. abscessus subsp. abscessus will predict inducible macrolide susceptibilit

300 ve not demonstrated cross-transmission of M. abscessus within our hospital, except between 1 sibling